"Day by day, what you choose, what you think, and what you do is who you become." Heraclitus #FridayMotivation

This excellent 📊👇 - from Stifel’s comprehensive BioTech & Pharma market outlook, tells the story of maybe the most important & fundamental development in the BioTech & Pharma global ecosystem over the past few years - the exponential growth of the Chinese 🇨🇳 BioTech sector and the way in which it has successfully transformed itself from a manufacturing-oriented industry into a cutting-edge innovative hub! Not only almost one-third of all global licensing deals signed in 2025 by Big Pharma companies were made with Chinese BioTech companies - the total upfront dollars paid by big Pharma for China licensing deals in the first 24 weeks of 2026 alone summed to a staggering amount of $4.5B (!) - compared to $5.1B in 2025 & to $12.9B in the entire period between 2019 and 2025. The acceleration is unprecedented!

Impressive results for $BEAM thanks for sharing @zhaoweiasu

Agree with your take here, should bode well for biotech names like $LEGN (no position, NFA, DYOR)

My uninformed guess as to why FB is so over staffed is because of “cheap money”, meaning that the company could borrow at low interest rates to hire more employees in order to expand their business; once the “punch bowl” was removed, FB needed to cut back on their staffing to continuously hit their quarterly earnings (could be wrong, no position, NFA)

June 12, 1991: 35 Years ago today, In Game 5 of The NBA Finals, The Bulls defeat The Lakers 108-101 to win their first ever NBA Championship. #ChicagoHistory 🏀

Thank you for this Mark

Terrific check list on what to look for when buying unusual options contracts for equities from one of the best options traders on X @7StarMike

Very bearish for quality of life in the United States and any country influenced by our social media. You don’t hold a door open for someone you don’t trust. It raises the cost of doing business. And people will live more solitary sadder lives, because they don’t trust. The demographic trends in the US are much worse than people realize. Not only are high trust people being replaced by low trust ones, Zoomers (Gen Z) are measurably dumber than their preceding generations (no school for 2-3 years, cell phones in class, etc). I’ve written before about super Zoomers, kids who used AI and YouTube to outpace preceding generation’s best so I’m saying this applies to all Zoomers, but the data on average is the data on average. These changes aren’t noticeable year to year but over 10 years, you reflect and think “whoa things are different”. Education can fix both these problems but the US’s current solution is to give up, to get as many kids out of the system as possible. I’m not kidding. We as a nation think it’s so unfixable, many states are moving to a voucher program where instead of going to a local public school, they get money that would have been allocated to that school which parents can spend on the child. Unthinkable in most countries I think. Must get worse before it gets better I think.

Casey's $CASY beat earnings by 30% and everyone seems to be incorrectly crediting the fuel margins. Wrong lesson, this is a food play. The real story: a gas station grew PIZZA sales 6.6% with NEGATIVE pricing while expanding margins 170 bps. Every restaurant chain in America spent two years RAISING prices to hit comps. Casey's cut prices and won on volume. When your competitors price out their own customers, you don't need to be great... you just need to be there. The trade-down economy has a winner and it sells gas. They are absolutely cutting into the Dominos $DPZ Papa Johns $PZZA Pizza Hut $YUM and more market share....not the handmade independents.

1/🚨WOW! Tune Therapeutics has just presented positive clinical data from its phase 1b/2a trial aimed to evaluated the safety and tolerability of TUNE-401 - a first-in-class Epigenetic silencer 🧵👇for Patients with Chronic Hepatitis B (CHB). @tunetx_news clinical data demonstrated deep and durable antiviral activity - making it the first clinical evidence of epigenetic silencing in hepatitis B virus (HBV), thus offering a possible new therapeutic pathway for HBV patients.

Scientists just created a Non-Invasive Ultrasound wearable pacemaker that can regulate heartbeats without implanted wires or electrodes. The system uses a 2.5 cm × 2.5 cm wearable ultrasound patch placed on the chest. It is based on sonogenetics, a technique that uses sound waves to remotely control genetically engineered cells inside the body. The team engineered heart muscle cells to express MscL-G22S, an ultrasound-sensitive mechanosensitive ion channel. When ultrasound reaches these cells, the channels open, allowing calcium ions to enter and trigger a heartbeat. Ultrasound → MscL-G22S activation → Calcium influx → Heartbeat The researchers successfully paced engineered human heart cells and restored normal heart rhythms in rats. The system achieved less than 1 mm targeting precision and pacing frequencies up to 9 Hz (540 beats per minute). Even more impressive, it maintained a favorable safety profile during 8 months of animal testing. The team also demonstrated the approach in porcine (pig) hearts, suggesting potential for future human-scale applications. This study is one of the strongest demonstrations yet that wearable ultrasound technology can noninvasively control deep organs.

Well…

we are probably 6 to 12 months away from the first pill designed to make you biologically younger today just changed the stakes the first ever reverse-aging drug was just injected into a human. Life Biosciences. David Sinclair. today, an actual human patient. here is everything pointing at the same moment: - Sinclair is also testing an oral reprogramming pill in the $101M XPRIZE. whole-body rejuvenation. a 10-year biological age improvement in one year of treatment - scientists just discovered ABT-263 dramatically reverses aging in skin and speeds wound healing. topical. already works - NewLimit raised $435M from Peter Thiel to deliver age reprogramming to the liver - semaglutide slowed biological aging by 9% on epigenetic clocks. a diabetes drug doing this on the side the convergence is coming bio/acc.

I remember watching Bulls play by play with Neil Funk and Stacey King, and they complemented each other’s style; King was great breaking down plays and had a knack for hyping great plays! A joy to watch - Stacey was a blessing, and his energy will be missed! 🙏 to his family!

So here is an example of how to build a better trade than a large player. Someone bought $nok Jan 34 calls 3500x today. My database builds a better trade by selling put spreads below the 8 week and using that to buy a call spread 17/19 in a 2x1 ratio. Now you get paid to go long.

Here’s the smoking gun if you’re scratching your head over $abvx , after pooling in the evidence I’m comfortable to stay long. Sharing with you all so you can rest better. 2yr rat carc and 6 mo mouse data in Obe had no malignancy signal (verified by a number of buyside and sellside folk today). No signal in the Ph2b and protocol was the same as Ph3 to pick up malignancies. Pod bros are dumb which is why they perform so terribly let them convince each other of their dumb narrative but we don’t have to wait 12 months to know that the cumulative weight of evidence against drug caused malignancy is genuinely substantial. Happy for any onco folk to chime in but 44 weeks is shorter than the shortest documented cancer latency period for de novo carcinogenesis in any tumor type. A drug cannot initiate cancer that becomes clinically detectable within 10 mo unless it’s working through a mechanism qualitatively different from carcinogenesis as understood. Which typically only if it acts as a tumor promoter (accelerating growth of already established but subclinical tumors) rather than as a tumor initiator. Obe CANNOT and is not causing cancer but is there something in the mechanism that promotes pre existing sub clinical cancer? Well a clean rat mouse carc package is the gold standard nonclinical evidence that a chronic use drug is not carcinogenic. Which is why there will be no black box! No signal here is amazing historically, drugs that clear 2 yr rat carc cleanly very rarely turn out to have human carcinogenicity that emerges in post marketing surveillance. Rodent carc studies have systematic mandated histopathology of every major organ system at termination plus interim deaths. They detect tumors at much lower thresholds than clinical AE reporting. I’m so done with Pod bros ducking dummies crying oh but MoA , miR 124 is one of the MOST extensively studied tumor suppressor microRNAs. Instead of going for beers and dinners for ideas do some research. That helps! Speaking on consensus (which they guys love and just follow what one says without any own work), there’s a unified stable scientific consensus across multiple labs and tumor types over 15 years of research. The mechanistic prior for miR 124 enhancement is ANTI CANCER, not pro cancer. Oh but.. off target effects ABX464.. omg since ABX464 binds the cap binding complex which has functions beyond miR 124 induction.. find me ONE published evidence linking CBC modulation to carcinogenesis and jbtw a tumor promoting off target effect would have surfaced in the 2 yr rat carc. ABX464 is non genotoxic across the full ICH S2 panel! Per the Phase 2b OLE Study 108 extension: •~217 patients on 50 mg for up to 96 weeks (Ph 2b OLE) •~130 patients de escalated to 25 mg for up to 5 additional years (Study 108) •Total cumulative exposure ~7 years •Monthly visits in Yr 1 quarterly in Yr 2 •Mandatory flexible sigmoidoscopy with rectal/sigmoidal biopsies at Week 48 and Week 96 •No malignancy signal . ZERO Even accounting for the imperfect surveillance for non colonic cancers (no scheduled mammography or PSA), the colonic surveillance was rigorous AND would have detected the dysplasia events that showed up in Ph 3. ZERO in ~800 pt yrs of active surveillance IS MEANINGFUL. More Context: Ph 3 50 mg arm: 3 non NMSC 4 NMSC in ~165 PY •One sided Fisher’s/Poisson p = ~0.13 for non NMSC vs pbo •Mean cancer case age 62 vs trial mean ~42 •SIR vs SEER age standardized rates: combined SIR ~3-6 if you weight by the trial age distribution •BUT pbo and 25 mg arms ran below SEER baseline (SIR ~0-1), which is part of why the 50 mg arm looks elevated by direct comparison •Investigator deemed unrelated for all cases •2 of 4 NMSC dismissed as not/unlikely related •1 had prior NMSC history The only 2 arguments that are left are: The cynomolgus immunosuppression finding in the primate study… and the dose response pattern cotd below

"So the opportunity, the headroom for us in chicken, is really quite significant," $MCD CEO Chris Kempczinski on adding breaded bone-in chicken wings to their test menu The margins for $WING and Chik-fil-A is an opportunity for McDonalds' to take market share *NFA, no postion

Congrats to you and the @unusual_whales team! Keep up the great work!

This is actually insane. 97% of people taking the standard of care for metastatic solid tumor got worse by seven years. But with lorlatinib, that number was only 45% in the same time! This is an ENORMOUS jump in the quality of cancer care.

The Baker Brothers - or under its official name “Baker Bros. Advisors LP”, is by far the biggest “Healthcare only” investment firm in the BioTech and Pharma ecosystem - managing $28.1B of Assets Under Management (AUM) 🧵👇. Just for comparison - the second biggest investment firm - orbimed - is far behind with “only” $20.6B of assets under its management. The story of the “Baker Brothers” is a story of both patience and persistence that played a huge rule in their biggest investment ever - Seagen (formally known as Seattle Genetics). Julian and Felix Baker began investing in Seagen in 2003 when they made their initial investment while the company had no drugs on the market and was barely breaking even. In order to strengthen the company’s leadership Felix Baker joined Seagen's board of directors and played a leading role in its long-term strategy. Up until 2023 the investment firm maintained its high conviction and substantial stake and took part in the company’s strategic plans and operations. In March of 2023 $PFE announced an all-cash acquisition of Seagen for $43 billion or $229 per share - one of the biggest M&A deals ever made in the BioTech and Pharma ecosystem. In December of that year the deal was officially closed and the Baker Brothers received $10 billion in cash for their stake in the company. This was and still is one of the largest single Return on Investment (ROI) in BioTech history. A truly remarkable story!